Solids almost certainly pose more of an aspiration risk than liquids
276 Lauffenburgers early modeling revealed how negative feedback quantitatively controls MAPK signal adaptation, and his concept of temporal collateral sensitivity shows that tumor evolution creates transient windows of drug susceptibility, supporting adaptive therapy
Over the last few years, GLP-1 medications have been approved with indications strictly for weight loss and chronic weight management by the U.S
But ultimately, it has to be affordable. With clients sending UnitedHealth Group a very, very clear signal that they need help making GLP-1s more attractive for their employees and members, Witty said UnitedHeath Group is focused on finding a way to make this sustainable and affordable. To do that, executives are working with drug manufacturers to get to some aligned value-based constructs, getting pricing to a point where its based on outcomes and adherence levelsall the way to outright risk on utilization levels, said Brian Thompson, CEO of UnitedHealthcare, the health benefits arm of UnitedHealth Group